卢比普罗可降低MRI-PDFF上的脂肪含量,在患有MASLD的患者中:一个48周的随机对照试验
Mohamed El-Kassas1,2,3, Hala Mostafa1, Wessam Abdellatif4
1Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Alimentary pharmacology & therapeutics
|January 2, 2025
概括
在与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者中,48周的卢比普罗治疗显著降低了肝脂肪. 这项研究表明,lubiprostone是MASLD的有前途的治疗选择,具有良好的耐受性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的健康问题.
- 目前对MASLD的治疗选择有限.
- 作为药的卢比普,已证明对肠道透性有影响.
研究的目的:
- 为了评估在患有MASLD的患者中 lubiprostone 的安全性和有效性.
- 为了评估48周的 lubiprostone 给药对肝脏脂肪含量的影响.
主要方法:
- 进行了一项为期48周的随机化安慰剂对照试验.
- 116名符合条件的患有MASLD的患者随机分配给接受安慰剂或 lubiprostone (24微克每天两次).
- 使用MRI-PDFF量化肝脏脂肪含量;纤维化和ALT水平也被评估.
主要成果:
- 与安慰剂相比,lubiprostone显著降低了肝脏脂肪含量 (p=0.04).
- 两组之间在纤维化得分或ALT水平上没有发现显著差异.
- 一名患者出现了严重的腹,导致治疗中止;否则, lubiprostone 耐受性良好.
结论:
- 在48周的时间里,卢比普罗有效地减少了MASLD患者的肝脂肪.
- 治疗耐受性良好,副作用最小.
- 需要进一步的广泛研究来证实 lubiprostone 在治疗 MASLD 的有效性.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
770
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
11.9K
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131
01:17Drugs for Treatment of Diarrhea-Predominant IBS
146
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
146
01:20Drugs Affecting GI Tract Motility: Other Laxatives
164
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
164